- Drugs
- Wednesday, 15 Jul 2020
AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate
Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker’s potential COVID-19 vaccine in the United States.
The collaboration is part of the U.S. government’s Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.
AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.
The agreement includes an expansive study of trial participants and will use IQVIA’s virtual trial solutions that would make parts of the study remote.
Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.
Related Industry Updates
Epilepsy Market is expected to reach US$ 10.7 billion by 2030
Feb 14, 2024
Ion Channel Modulators Market - Segmentation, Manufacturing Cost Analysis Including Key Raw Materials, Price Trend, Key Suppliers and Forecast 2027
Mar 09, 2021
Nasal Polyps Treatment Market Size will Escalate Rapidly in the Near Future 2020: Forecast 2027 by OptiNose US, Inc. , Regeneron Pharmaceuticals, Inc. , Merck KGaA , Pfizer, Inc.
Apr 09, 2021
Esteve acquires German proprietary, specialty, hospital-focused company Riemser and expands its presence in Europe
Jan 08, 2020
Is Hydroxychloroquine Really a Game Changer in the fight against COVID-19?
Apr 15, 2020
Malaria and Sickle Cell Disease Treatment Market is expected to reach US$ 29,179.60 million by 2030
Nov 03, 2023
United Cannabis Corporation Receives Notice of Allowance for New Patent Covering Methods of Preparing and Using Cannabinoid Formulations
Dec 12, 2019
Follow us on
